CN111972664A - 一种保健胶囊 - Google Patents
一种保健胶囊 Download PDFInfo
- Publication number
- CN111972664A CN111972664A CN202010797892.8A CN202010797892A CN111972664A CN 111972664 A CN111972664 A CN 111972664A CN 202010797892 A CN202010797892 A CN 202010797892A CN 111972664 A CN111972664 A CN 111972664A
- Authority
- CN
- China
- Prior art keywords
- capsule
- health
- cells
- composition
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 63
- 239000000203 mixture Substances 0.000 claims abstract description 50
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 28
- 230000036541 health Effects 0.000 claims abstract description 26
- 229940088594 vitamin Drugs 0.000 claims abstract description 19
- 229930003231 vitamin Natural products 0.000 claims abstract description 19
- 235000013343 vitamin Nutrition 0.000 claims abstract description 19
- 239000011782 vitamin Substances 0.000 claims abstract description 19
- 244000299461 Theobroma cacao Species 0.000 claims abstract description 13
- 235000009470 Theobroma cacao Nutrition 0.000 claims abstract description 13
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229940110456 cocoa butter Drugs 0.000 claims abstract description 12
- 235000019868 cocoa butter Nutrition 0.000 claims abstract description 12
- 239000006041 probiotic Substances 0.000 claims abstract description 12
- 235000018291 probiotics Nutrition 0.000 claims abstract description 12
- 235000011187 glycerol Nutrition 0.000 claims abstract description 11
- 239000000843 powder Substances 0.000 claims abstract description 11
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 10
- 239000008101 lactose Substances 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 102000008186 Collagen Human genes 0.000 claims abstract description 8
- 108010035532 Collagen Proteins 0.000 claims abstract description 8
- 108010010803 Gelatin Proteins 0.000 claims abstract description 8
- 229920000159 gelatin Polymers 0.000 claims abstract description 8
- 239000008273 gelatin Substances 0.000 claims abstract description 8
- 235000019322 gelatine Nutrition 0.000 claims abstract description 8
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 8
- FZAQROFXYZPAKI-UHFFFAOYSA-N anthracene-2-sulfonyl chloride Chemical compound C1=CC=CC2=CC3=CC(S(=O)(=O)Cl)=CC=C3C=C21 FZAQROFXYZPAKI-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229920001436 collagen Polymers 0.000 claims abstract description 6
- 239000004408 titanium dioxide Substances 0.000 claims abstract description 6
- 239000008159 sesame oil Substances 0.000 claims description 14
- 239000002285 corn oil Substances 0.000 claims description 8
- 235000005687 corn oil Nutrition 0.000 claims description 8
- 239000000341 volatile oil Substances 0.000 claims description 8
- 235000007215 black sesame Nutrition 0.000 claims description 6
- 235000019486 Sunflower oil Nutrition 0.000 claims 2
- 239000002600 sunflower oil Substances 0.000 claims 2
- 241000282414 Homo sapiens Species 0.000 abstract description 74
- 230000000694 effects Effects 0.000 abstract description 30
- 230000032683 aging Effects 0.000 abstract description 15
- 235000015112 vegetable and seed oil Nutrition 0.000 abstract description 13
- 239000008158 vegetable oil Substances 0.000 abstract description 12
- 239000000126 substance Substances 0.000 abstract description 11
- 230000009286 beneficial effect Effects 0.000 abstract description 10
- 210000005260 human cell Anatomy 0.000 abstract description 9
- 230000008901 benefit Effects 0.000 abstract description 7
- 210000004027 cell Anatomy 0.000 description 66
- 201000011510 cancer Diseases 0.000 description 34
- 206010028980 Neoplasm Diseases 0.000 description 32
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 27
- 229950006238 nadide Drugs 0.000 description 27
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 24
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 20
- 230000006870 function Effects 0.000 description 20
- 230000004060 metabolic process Effects 0.000 description 19
- 210000003470 mitochondria Anatomy 0.000 description 18
- 108091035539 telomere Proteins 0.000 description 18
- 210000003411 telomere Anatomy 0.000 description 18
- 102000055501 telomere Human genes 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 16
- 102000009025 Endorphins Human genes 0.000 description 12
- 108010049140 Endorphins Proteins 0.000 description 12
- 235000012000 cholesterol Nutrition 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 229930003427 Vitamin E Natural products 0.000 description 10
- 210000000349 chromosome Anatomy 0.000 description 10
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 235000019165 vitamin E Nutrition 0.000 description 10
- 239000011709 vitamin E Substances 0.000 description 10
- 229940046009 vitamin E Drugs 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 210000001161 mammalian embryo Anatomy 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 235000011803 sesame oil Nutrition 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 235000020238 sunflower seed Nutrition 0.000 description 7
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 6
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 230000001093 anti-cancer Effects 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 239000005515 coenzyme Substances 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 230000008439 repair process Effects 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 102000011724 DNA Repair Enzymes Human genes 0.000 description 4
- 108010076525 DNA Repair Enzymes Proteins 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- 108010017842 Telomerase Proteins 0.000 description 4
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 230000019522 cellular metabolic process Effects 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- -1 etc. Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 235000021588 free fatty acids Nutrition 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 208000019622 heart disease Diseases 0.000 description 4
- 210000003016 hypothalamus Anatomy 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 210000003463 organelle Anatomy 0.000 description 4
- 230000001817 pituitary effect Effects 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 210000001082 somatic cell Anatomy 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 4
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- PEYUIKBAABKQKQ-AFHBHXEDSA-N (+)-sesamin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-AFHBHXEDSA-N 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- GIDHDUYAXIVIMN-JJORJHTQSA-N CCC(=O)O[C@@H]1CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O[C@H]2CC[C@@H]([C@@H](C)O2)N(C)C)[C@H](C)C[C@H](CC=O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@H]1OC Chemical compound CCC(=O)O[C@@H]1CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O[C@H]2CC[C@@H]([C@@H](C)O2)N(C)C)[C@H](C)C[C@H](CC=O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@H]1OC GIDHDUYAXIVIMN-JJORJHTQSA-N 0.000 description 2
- PNMQDIDLWTXQLZ-RZELCZIWSA-N CO[C@H]1[C@@H](CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O[C@H]2CC[C@@H]([C@@H](C)O2)N(C)C)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C)OC(C)=O Chemical compound CO[C@H]1[C@@H](CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O[C@H]2CC[C@@H]([C@@H](C)O2)N(C)C)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C)OC(C)=O PNMQDIDLWTXQLZ-RZELCZIWSA-N 0.000 description 2
- GCIQAGXAZPUQNA-YDPAJNKASA-N CO[C@H]1[C@H](O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O[C@H]2CC[C@@H]([C@@H](C)O2)N(C)C)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C Chemical compound CO[C@H]1[C@H](O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O[C@H]2CC[C@@H]([C@@H](C)O2)N(C)C)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C GCIQAGXAZPUQNA-YDPAJNKASA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 2
- 241001539473 Euphoria Species 0.000 description 2
- 206010015535 Euphoric mood Diseases 0.000 description 2
- 206010064571 Gene mutation Diseases 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 2
- 108020005196 Mitochondrial DNA Proteins 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 2
- 239000013616 RNA primer Substances 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 229930003270 Vitamin B Natural products 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- TTWYZDPBDWHJOR-IDIVVRGQSA-L adenosine triphosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O TTWYZDPBDWHJOR-IDIVVRGQSA-L 0.000 description 2
- 230000003281 allosteric effect Effects 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 238000005842 biochemical reaction Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000011712 cell development Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 208000026758 coronary atherosclerosis Diseases 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002857 effect on ulcer Effects 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 210000002308 embryonic cell Anatomy 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- PEYUIKBAABKQKQ-UHFFFAOYSA-N epiasarinin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-UHFFFAOYSA-N 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 208000001130 gallstones Diseases 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000003701 histiocyte Anatomy 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 2
- 238000006317 isomerization reaction Methods 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000001050 lubricating effect Effects 0.000 description 2
- 239000002932 luster Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229910001425 magnesium ion Inorganic materials 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 102000051367 mu Opioid Receptors Human genes 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 201000000585 muscular atrophy Diseases 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 235000021313 oleic acid Nutrition 0.000 description 2
- 239000003605 opacifier Substances 0.000 description 2
- 229940127240 opiate Drugs 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000010627 oxidative phosphorylation Effects 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 210000003635 pituitary gland Anatomy 0.000 description 2
- 210000001778 pluripotent stem cell Anatomy 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- VRMHCMWQHAXTOR-CMOCDZPBSA-N sesamin Natural products C1=C2OCOC2=CC([C@@H]2OC[C@@]3(C)[C@H](C=4C=C5OCOC5=CC=4)OC[C@]32C)=C1 VRMHCMWQHAXTOR-CMOCDZPBSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 201000005060 thrombophlebitis Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 2
- 210000001186 vagus nerve Anatomy 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 235000019163 vitamin B12 Nutrition 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- 235000019158 vitamin B6 Nutrition 0.000 description 2
- 239000011726 vitamin B6 Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 239000011647 vitamin D3 Substances 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- 235000005282 vitamin D3 Nutrition 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- 229940021056 vitamin d3 Drugs 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 108020001612 μ-opioid receptors Proteins 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- RPABDKTXMKOGKI-OYTUFZPASA-N 6-methyl-n-[2-[(2s,5s,8s,11s,14s,17s,20s,23s)-8,11,14,20-tetrakis(2-aminoethyl)-5-[(1r)-1-hydroxyethyl]-17,23-bis(2-methylpropyl)-3,6,9,12,15,18,21,24-octaoxo-1,4,7,10,13,16,19,22-octazacyclotetracos-2-yl]ethyl]octanamide Chemical compound CCC(C)CCCCC(=O)NCC[C@@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H]([C@@H](C)O)NC1=O RPABDKTXMKOGKI-OYTUFZPASA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010078777 Colistin Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 230000003679 aging effect Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000002451 diencephalon Anatomy 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003688 hormone derivative Substances 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 230000008621 organismal health Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/015—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/275—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of animal origin, e.g. chitin
- A23L29/281—Proteins, e.g. gelatin or collagen
- A23L29/284—Gelatin; Collagen
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
- A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
- A23P10/35—Encapsulation of particles, e.g. foodstuff additives with oils, lipids, monoglycerides or diglycerides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明提供一种保健胶囊。本发明属于保健品技术领域,涉及一种保健胶囊。该胶囊包括胶囊壳体和胶囊内组合物,所述胶囊壳体包括如下质量百分比组分:明胶:40‑60%,可可粉:1‑3%,可可脂:1.5‑3%,甘油:8‑15%,二氧化钛:0.5‑1%,余量的水;所述胶囊内组合物包括如下质量百分比组分:β‑烟酰胺单核苷酸:2‑5%,胶原蛋白:2‑5%,异构化乳糖:3‑7%,植物甾醇:0.2‑0.5%,余量的水。与现有技术相比,本发明具有如下优点和效果:首先,本发明可以有效的减缓人体细胞的衰老,延长人体的寿命;其次,本发明的组分中含有植物油、维生素、益生菌等对人体有益的物质,可以有助于人体的健康;最后,本发明的胶囊壳体含有可可粉、可可脂等物质,能够增强胶囊的口感。
Description
技术领域
本发明属于保健品技术领域,涉及一种保健胶囊。
背景技术
随着经济高速发展和工业化进程的加速,生活方式的改变和老龄化进程的加速,衰老是老龄化社会持续关注的社会和经济问题之一,2020年,全国60 岁以上老年人口将增加到2.55亿人左右,如何保证老人的健康是一项迫在眉睫的难题。
现有技术公开了专利号为CN201910047903.8的一种延缓衰老和/或延长寿命的组合物及其用途,所述的组合物包括第一活性成分,所述的第一活性成分为可利霉素、异戊酰螺旋霉素Ⅰ、异戊酰螺旋霉素Ⅱ、异戊酰螺旋霉素Ⅲ之一,或者异戊酰螺旋霉素Ⅰ、异戊酰螺旋霉素Ⅱ、异戊酰螺旋霉素Ⅲ两种或三种的组合。该组合物虽然对延长老人寿命有益,但依然存在效果不明显的问题,且该组合物对人体健康作用不明显。
发明内容
为了解决上述问题,本发明的首要目的在于提供一种保健胶囊,该胶囊能有效的减缓人体细胞的衰老。
本发明的另一个目的在于提供一种保健胶囊,该胶囊能够有益于人体的健康。
本发明的最后一个目的在于提供一种保健胶囊,该胶囊具有优异的口感。
为了实现上述目的,本发明的技术方案如下。
本发明提供一种保健胶囊,该胶囊包括胶囊壳体和胶囊内组合物,该胶
囊壳体包括如下质量百分比组分:
明胶:40-60%,
可可粉:1-3%,
可可脂:1.5-3%,
甘油:8-15%,
二氧化钛:0.5-1%,
余量的水。
进一步的,所述明胶为食用明胶,是一种强有力的保护胶体,乳化力强,进入胃后能抑制牛奶、豆浆等蛋白质因胃酸作用而引起的凝聚作用,从而有利于胶囊的消化。
进一步的,所述可可粉具有浓烈的可可香气且具有减肥,降压,安神的功效,用于制作胶囊外壳即可以增强胶囊的口感,也对人体有非常大的好处。
进一步的,所述可可脂含有丰富的多酚,具有抗氧化功能,可以保护人体对抗一系列疾病,减轻老化影响;且可可脂香味纯正、浓郁,入口软滑,具有润滑的质感和香甜的气味。将可可脂用于制作胶囊外壳可调节胶囊的可感也同时使胶囊具有益于人体的功能。
进一步的,所述甘油又称“丙三醇”,所述甘油具有很强的吸湿性,加入胶囊外壳中,能够保持胶囊外壳的韧性,防止胶囊壳太干燥而破裂。
进一步的,所述二氧化钛作为“遮光剂”,具有优异紫外光屏蔽性和透明性。
该胶囊内组合物包括如下质量百分比组分:
β-烟酰胺单核苷酸:2-5%,
胶原蛋白:2-5%,
异构化乳糖:3-7%,
黑芝麻油:15-30%,
沉香精油:0.5-1%,
玉米油:5-15%,
葵花籽油:5-15%,
维生素:1-3%,
益生菌:0.5-1%,
植物甾醇:0.2-0.5%,
余量的水。
进一步的,所述β-烟酰胺单核苷酸,简称“NMN”,能够参与细胞内NAD(烟酰胺腺嘌呤二核苷酸,细胞能量转化的重要辅酶)的合成。NAD辅酶在人类衰老的过程中起到很重要的作用,补充NAD和NMN,可以提高人体基础代谢,改善血液微循环,从而有效的抵御衰老的进程。同时,NMN本身也具有改善睡眠、提高记忆力、抗衰老等作用,加入到本组合物中,可以有效的增强人的寿命。
进一步的,所述胶原蛋白分子肽链上具有多种反应基团,如羟基、羧基和氨基等,易于吸收和结合多种酶和细胞,实现固定化,它具有与酶和细胞亲合性好、适应性强的特点。胶原蛋白具有良好的生物特征,在组织和器官形成中具有重要作用。
进一步的,所述异构化乳糖是一种益生元,具有增殖双歧杆菌、改善肠道环境和提高肠道健康的功能。异构化乳糖同时可以促成结肠内形成酸性环境,进而促使钙镁离子的吸收。
进一步的,所述黑芝麻油,又称“香油”。具有浓郁的香气,可促进食欲,帮助消化。它富含亚油酸、油酸、亚麻酸等不饱和脂肪酸,容易被人体分解、吸收和利用,以促进胆固醇的代谢,并有助于消除动脉血管壁上的沉积物,对防治心血管疾病有一定的作用;香油中含量仅占0.5%的芝麻素具有优异的抗氧化作用,可以保肝护心,延缓衰老,同时芝麻素还具有良好的抗癌功能。香油中还含丰富的维生素E,具有促进细胞分裂和延缓衰老的功能。香油还有润肠通便,润嗓利咽的功效。
进一步的,所述沉香精油是由珍贵的沉香经过蒸馏萃取后提炼而成的,对人体有着多重功效,例如:改善气场、舒缓压力、安眠抗郁、调理身心和促进身体新城代谢等。
进一步的,所述玉米油对于血液中胆固醇的积累具有溶解作用,能减少对血管产生硬化影响,对老年性疾病如动脉硬化、糖尿病等具有积极的防治作用。且玉米油中含有天然复合维生素E,对心脏疾病、血栓性静脉炎、生殖机能类障碍、肌萎缩症、营养性脑软化症均有明显的疗效和预防作用。
进一步的,所述葵花籽油含有甾醇、维生素、亚油酸等多种对人类有益的物质,其中天然维生素E含量在所有主要植物油中含量最高,可以促进人体细胞的再生和成长,保护皮肤健康,并能减少胆固醇在血液中的淤积,对人体具有很大的好处。
进一步的,所述维生素包括维生素A、维生素B、维生素C、维生素D、维生素E,所述维生素维生素是人生长所必需的某些少量有机化合物,对机体的新陈代谢、生长、发育、健康有极重要作用。维生素参与人体中不断地进行着各种生化反应,是维持和调节机体正常代谢的重要物质。
进一步的,所述益生菌能促进营养物质的消化吸收、提高机体免疫力、维持肠道菌群结构平衡、提高机体抗氧化水平、抑制肠道炎症、保护肠道粘膜屏障。
进一步的,所述植物甾醇对人体具有较强的抗炎作用,具有能够抑制人体对胆固醇的吸收、促进胆固醇的降解代谢、抑制胆固醇的生化合成等作用;也可用于预防治疗冠状动脉粥样硬化类的心脏病,对治疗溃疡、皮肤鳞癌、宫颈癌等有明显的疗效;可促进伤口愈合,使肌肉增生、增强毛细血管循环;还可作为胆结石形成的阻止剂;同时,植物甾醇还是重要的甾体药物和维生素D3 的生产原料。
进一步的,本配方的作用机理为,本配方主要由蛋白质和植物油加NMN 主要组成,蛋白质是组成人体一切细胞、组织的重要成分。机体所有重要的组成部分都需要有蛋白质的参与。一般说,蛋白质约占人体全部质量的18%,最重要的还是其与生命现象有关。植物油是由不饱和脂肪酸和甘油化合而成的化合物,植物油主要含有维生素E、K、钙、铁、磷、钾等矿物质、脂肪酸等。植物油中的脂肪酸能使皮肤滋润有光泽。NMN是NAD+最直接的前体,是人体内天然存在的物质,也存在于很多食物当中,尚未发现任何毒副作用。NAD+ 俗称辅酶I,全称烟酰胺腺嘌呤二核苷酸。NAD+存在于人体的每一个细胞中,广泛的参与营养物质的代谢和能量的合成。其中,NAD+是三羧酸循环的重要辅酶,参与糖,脂肪和氨基酸的代谢,同时以ATP(三磷三腺苷)的形式释放能量,推动细胞发展。相关研究还发现NAD+是DNA修复酶PARP的唯一底物,通俗来讲就是NAD+可以提高DNA修复酶的活性,更加有效的修复受损的DNA,预防由于基因突变造成的疾病,比如说恶性肿瘤。植物油中的游离脂肪酸于NMN粘合进入细胞膜内,作用细胞内线粒体磷酸化产生ATP。
人类有有类细胞出生后就没再发育,人体各个组织里都有,且数量巨大,约占人的细胞总数量的四分一,这种原始胚胎细胞,在体外均可以培养成万能干细胞,从而转变成人的各种组织和器官,那么在体内可以吗?事实证明也可以,以皮肤器官为例,许多人烧伤,割伤后仍然长出完整皮肤,皮肤器官可以,那么人体其它器官也同样可以,只要在人体内有相应的营养物资,满足一定条件是完全可以行得通的。人体内原始胚胎细胞被激活后变成万能干细胞,万能干细胞又变成人的各种组织细胞去取代老死或变异细胞,这样人的寿命可以延长。
防癌机理,人体内原始胚胎细胞被激活后,其免疫功能也同样变得强大,也自然不会轻易得癌了。抗癌机理,人得了癌,是因基因不构稳定,在外部因素影响下造成突变行成的。癌细胞有个共同特点就是都为永生细胞,因为癌细胞内的端粒体有端粒酶,这东西可以修复端粒体即自我修复功能,即增殖分裂后,缩短的端粒体可以自动恢复到原来长度,按照生命端粒体学说,端粒体长度也决定了生命长度,因为癌细胞内的端粒体有自我修复功能,所以癌细胞就成为永生细胞。而人的正常细胞就不会,增殖分裂后,端粒体就会缩短点,生命也就会短点。(端粒(Telomere)是染色体的末端部分,这一特殊结构区域对于线型染色体的结构和稳定起重要作用。线性染色体的两个末端具有的特殊结构。端粒的功能为稳定染色体末端结构,防止染色体间末端连接,并可补偿滞后链末端在消除RNA引物后造成的空缺。组织培养的细胞证明,端粒在决定动植物细胞的寿命中起着重要作用,经过多代培养的老化细胞端粒变短,染色体也变得不稳定。端粒体,它位于DNA的两端,随着年龄的增长,它越来越短,直到最后由于它过短了,无法分裂了,生命就死亡了。)正是这种差别让我们有了区别他们的办法。线粒体,是一种存在于大多数细胞中的由两层膜包被的细胞器,直径在0.5到10微米左右。大多数真核细胞拥有线粒体,但它们各自拥有的线粒体在大小、数量及外观等方面上都有所不同。线粒体拥有自身的遗传物质和遗传体系,但因其基因组大小有限,所以线粒体是一种半自主细胞器。线粒体是细胞内氧化磷酸化和合成三磷酸腺苷(ATP)的主要场所,为细胞的活动提供了能量,细胞生命活动所需的能量95%来自线粒体。所以其又有“细胞动力工厂”之称。除了为细胞供能外,线粒体还参与诸如细胞分化、细胞信息传递和细胞凋亡等过程,并拥有调控细胞生长和细胞周期的能力。显然癌细胞线粒体与人正常细胞线粒体DNA完全不同,也就表示某些物资人的正常细胞可以代谢,而癌细胞却不能,当这些物资进入细胞内人的正常细胞不受影响,而癌细胞却会凋亡,凋亡的癌细胞会发出某种信号,被免疫系统识别,而被清除到体外,正常细胞会取代原来位置,从而恢复正常功能。本产品富含数百种对人有益的物资,其中有些物资进入癌细胞内,使癌细胞凋亡,这是一种广谱抗癌方法,远优于目前抗癌方法。
本产品配方富含人体必须多种维量原素:如钙,钾,铁,硒,镁,钠等,对维持人体的电解质平衡,细胞代谢至关重要。
本产品配方直接或间接富含人体必须多种维生素,如:异构化乳糖不易为人体吸收,却是肠道内益生菌主要食物,益生菌食用后,代谢产生大量B1, B6,B12维生素,为人体细胞代谢提供充足营养。
本产品癸花子油富含B3维生素,也是NAD+前体之一。
本产品的沉香精油,可以作用人的迷走神经系统,间脑中的垂体和下丘脑会源源不断的分泌内啡肽,内啡肽亦称安多芬或脑内啡,是一种内成性(脑下垂体分泌)的类吗啡生物化学合成物激素。它是由脑下垂体和脊椎动物的丘脑下部所分泌的氨基化合物(肽)。它能与吗啡受体结合,产生跟吗啡、鸦片剂一样的止痛效果和欣快感。等同天然的镇痛剂。在内啡肽的激发下,人的身心处于轻松愉悦的状态中,免疫系统实力得以强化,并能顺利入梦,消除失眠症。内啡肽有助于修复我们的身体,当内啡肽分泌的时候,你会觉得心情非常的宁静和喜悦,充满了力量和信心,使人愉乐,使人的分泌出好的激素,改善人的代谢和一些炎症,其中一些激素通过游离脂肪酸粘合进入细胞膜内,有效杀灭癌细胞。
本发明的有益效果在于,与现有技术相比,本发明具有如下优点和效果:首先,本发明可以有效的减缓人体细胞的衰老,延长人体的寿命;其次,本发明的组分中含有植物油、维生素、益生菌等对人体有益的物质,可以有助于人体的健康;最后,本发明的胶囊壳体含有可可粉、可可脂等物质,能够增强胶囊的口感。
具体实施方式
为了使本发明的目的、技术方案及优点更加清楚明白,以下结合实施例,对本发明进行进一步详细说明。应当理解,此处所描述的具体实施例仅仅用以解释本发明,并不用于限定本发明。
为实现上述目的,本发明的技术方案如下。
本发明提供一种保健胶囊,该胶囊包括胶囊壳体和胶囊内组合物,
该胶囊壳体包括如下质量百分比组分:
明胶:50%,
可可粉:2%,
可可脂:2%,
甘油:10%,
二氧化钛:0.8%,
余量的水。
在本实例中,所述明胶为食用明胶,是一种强有力的保护胶体,乳化力强,进入胃后能抑制牛奶、豆浆等蛋白质因胃酸作用而引起的凝聚作用,从而有利于胶囊的消化。
在本实例中,所述可可粉具有浓烈的可可香气且具有减肥,降压,安神的功效,用于制作胶囊外壳即可以增强胶囊的口感,也对人体有非常大的好处。
在本实例中,所述可可脂含有丰富的多酚,具有抗氧化功能,可以保护人体对抗一系列疾病,减轻老化影响;且可可脂香味纯正、浓郁,入口软滑,具有润滑的质感和香甜的气味。将可可脂用于制作胶囊外壳可调节胶囊的可感也同时使胶囊具有益于人体的功能。
在本实例中,所述甘油又称“丙三醇”,所述甘油具有很强的吸湿性,加入胶囊外壳中,能够保持胶囊外壳的韧性,防止胶囊壳太干燥而破裂。
在本实例中,所述二氧化钛作为“遮光剂”,具有优异紫外光屏蔽性和透明性。
该胶囊内组合物包括如下质量百分比组分:
β-烟酰胺单核苷酸:3.0%,
胶原蛋白:2.5%,
异构化乳糖:5.0%,
黑芝麻油:20.0%,
沉香精油:0.7%,
玉米油:10.0%,
葵花籽油:10.0%,
维生素:2.0%,
益生菌:0.7%,
植物甾醇:0.3%,
余量的水。
在本实例中,所述β-烟酰胺单核苷酸,简称“NMN”,能够参与细胞内 NAD(烟酰胺腺嘌呤二核苷酸,细胞能量转化的重要辅酶)的合成。NAD辅酶在人类衰老的过程中起到很重要的作用,补充NAD和NMN,可以提高人体基础代谢,改善血液微循环,从而有效的抵御衰老的进程。同时,NMN本身也具有改善睡眠、提高记忆力、抗衰老等作用,加入到本组合物中,可以有效的增强人的寿命。
在本实例中,所述胶原蛋白分子肽链上具有多种反应基团,如羟基、羧基和氨基等,易于吸收和结合多种酶和细胞,实现固定化,它具有与酶和细胞亲合性好、适应性强的特点。胶原蛋白具有良好的生物特征,在组织和器官形成中具有重要作用。
在本实例中,所述异构化乳糖是一种益生元,具有增殖双歧杆菌、改善肠道环境和提高肠道健康的功能。异构化乳糖同时可以促成结肠内形成酸性环境,进而促使钙镁离子的吸收。
在本实例中,所述黑芝麻油,又称“香油”。具有浓郁的香气,可促进食欲,帮助消化。它富含亚油酸、油酸、亚麻酸等不饱和脂肪酸,容易被人体分解、吸收和利用,以促进胆固醇的代谢,并有助于消除动脉血管壁上的沉积物,对防治心血管疾病有一定的作用;香油中含量仅占0.5%的芝麻素具有优异的抗氧化作用,可以保肝护心,延缓衰老,同时芝麻素还具有良好的抗癌功能。香油中还含丰富的维生素E,具有促进细胞分裂和延缓衰老的功能。香油还有润肠通便,润嗓利咽的功效。
在本实例中,所述沉香精油是由珍贵的沉香经过蒸馏萃取后提炼而成的,对人体有着多重功效,例如:改善气场、舒缓压力、安眠抗郁、调理身心和促进身体新城代谢等。
在本实例中,所述玉米油对于血液中胆固醇的积累具有溶解作用,能减少对血管产生硬化影响,对老年性疾病如动脉硬化、糖尿病等具有积极的防治作用。且玉米油中含有天然复合维生素E,对心脏疾病、血栓性静脉炎、生殖机能类障碍、肌萎缩症、营养性脑软化症均有明显的疗效和预防作用。
在本实例中,所述葵花籽油含有甾醇、维生素、亚油酸等多种对人类有益的物质,其中天然维生素E含量在所有主要植物油中含量最高,可以促进人体细胞的再生和成长,保护皮肤健康,并能减少胆固醇在血液中的淤积,对人体具有很大的好处。
在本实例中,所述维生素包括维生素A、维生素B、维生素C、维生素D、维生素E,所述维生素维生素是人生长所必需的某些少量有机化合物,对机体的新陈代谢、生长、发育、健康有极重要作用。维生素参与人体中不断地进行着各种生化反应,是维持和调节机体正常代谢的重要物质。
在本实例中,所述益生菌能促进营养物质的消化吸收、提高机体免疫力、维持肠道菌群结构平衡、提高机体抗氧化水平、抑制肠道炎症、保护肠道粘膜屏障。
在本实例中,所述植物甾醇对人体具有较强的抗炎作用,具有能够抑制人体对胆固醇的吸收、促进胆固醇的降解代谢、抑制胆固醇的生化合成等作用;也可用于预防治疗冠状动脉粥样硬化类的心脏病,对治疗溃疡、皮肤鳞癌、宫颈癌等有明显的疗效;可促进伤口愈合,使肌肉增生、增强毛细血管循环;还可作为胆结石形成的阻止剂;同时,植物甾醇还是重要的甾体药物和维生素D3 的生产原料。
在本实例中,本配方的作用机理为,本配方主要由蛋白质和植物油加NMN 主要组成,蛋白质是组成人体一切细胞、组织的重要成分。机体所有重要的组成部分都需要有蛋白质的参与。一般说,蛋白质约占人体全部质量的18%,最重要的还是其与生命现象有关。植物油是由不饱和脂肪酸和甘油化合而成的化合物,植物油主要含有维生素E、K、钙、铁、磷、钾等矿物质、脂肪酸等。植物油中的脂肪酸能使皮肤滋润有光泽。NMN是NAD+最直接的前体,是人体内天然存在的物质,也存在于很多食物当中,尚未发现任何毒副作用。NAD+ 俗称辅酶I,全称烟酰胺腺嘌呤二核苷酸。NAD+存在于人体的每一个细胞中,广泛的参与营养物质的代谢和能量的合成。其中,NAD+是三羧酸循环的重要辅酶,参与糖,脂肪和氨基酸的代谢,同时以ATP(三磷三腺苷)的形式释放能量,推动细胞发展。相关研究还发现NAD+是DNA修复酶PARP的唯一底物,通俗来讲就是NAD+可以提高DNA修复酶的活性,更加有效的修复受损的DNA,预防由于基因突变造成的疾病,比如说恶性肿瘤。植物油中的游离脂肪酸于NAD+粘合进入细胞膜内,作用细胞内线粒体磷酸化产生ATP。
人类有有类细胞出生后就没再发育,人体各个组织里都有,且数量巨大,约占人的细胞总数量的四分一,这种原始胚胎细胞,在体外均可以培养成万能干细胞,从而转变成人的各种组织和器官,那么在体内可以吗?事实证明也可以,以皮肤器官为例,许多人烧伤,割伤后仍然长出完整皮肤,皮肤器官可以,那么人体其它器官也同样可以,只要在人体内有相应的营养物资,满足一定条件是完全可以行得通的。人体内原始胚胎细胞被激活后变成万能干细胞,万能干细胞又变成人的各种组织细胞去取代老死或变异细胞,这样人的寿命可以延长。
防癌机理,人体内原始胚胎细胞被激活后,其免疫功能也同样变得强大,也自然不会轻易得癌了。抗癌机理,人得了癌,是因基因不构稳定,在外部因素影响下造成突变行成的。癌细胞有个共同特点就是都为永生细胞,因为癌细胞内的端粒体有端粒酶,这东西可以修复端粒体即自我修复功能,即增殖分裂后,缩短的端粒体可以自动恢复到原来长度,按照生命端粒体学说,端粒体长度也决定了生命长度,因为癌细胞内的端粒体有自我修复功能,所以癌细胞就成为永生细胞。而人的正常细胞就不会,增殖分裂后,端粒体就会缩短点,生命也就会短点。(端粒(Telomere)是染色体的末端部分,这一特殊结构区域对于线型染色体的结构和稳定起重要作用。线性染色体的两个末端具有的特殊结构。端粒的功能为稳定染色体末端结构,防止染色体间末端连接,并可补偿滞后链末端在消除RNA引物后造成的空缺。组织培养的细胞证明,端粒在决定动植物细胞的寿命中起着重要作用,经过多代培养的老化细胞端粒变短,染色体也变得不稳定。端粒体,它位于DNA的两端,随着年龄的增长,它越来越短,直到最后由于它过短了,无法分裂了,生命就死亡了。)正是这种差别让我们有了区别他们的办法。线粒体,是一种存在于大多数细胞中的由两层膜包被的细胞器,直径在0.5到10微米左右。大多数真核细胞拥有线粒体,但它们各自拥有的线粒体在大小、数量及外观等方面上都有所不同。线粒体拥有自身的遗传物质和遗传体系,但因其基因组大小有限,所以线粒体是一种半自主细胞器。线粒体是细胞内氧化磷酸化和合成三磷酸腺苷(ATP)的主要场所,为细胞的活动提供了能量,细胞生命活动所需的能量95%来自线粒体。所以其又有“细胞动力工厂”之称。除了为细胞供能外,线粒体还参与诸如细胞分化、细胞信息传递和细胞凋亡等过程,并拥有调控细胞生长和细胞周期的能力。显然癌细胞线粒体与人正常细胞线粒体DNA完全不同,也就表示某些物资人的正常细胞可以代谢,而癌细胞却不能,当这些物资进入细胞内人的正常细胞不受影响,而癌细胞却会凋亡,凋亡的癌细胞会发出某种信号,被免疫系统识别,而被清除到体外,正常细胞会取代原来位置,从而恢复正常功能。本产品富含数百种对人有益的物资,其中有些物资进入癌细胞内,使癌细胞凋亡,这是一种广谱抗癌方法,远优于目前抗癌方法。
在本实例中,所述本产品配方富含人体必须多种维量原素:如钙,钾,铁,硒,镁,钠等,对维持人体的电解质平衡,细胞代谢至关重要。
在本实例中,所述本产品配方直接或间接富含人体必须多种维生素,如:异构化乳糖不易为人体吸收,却是肠道内益生菌主要食物,益生菌食用后,代谢产生大量B1,B6,B12维生素,为人体细胞代谢提供充足营养。
在本实例中,所述本产品癸花子油富含B3维生素,也是NAD+前体之一。在本实例中,所述本产品的沉香精油,可以作用人的迷走神经系统,间脑中的垂体和下丘脑会源源不断的分泌内啡肽,内啡肽亦称安多芬或脑内啡,是一种内成性(脑下垂体分泌)的类吗啡生物化学合成物激素。它是由脑下垂体和脊椎动物的丘脑下部所分泌的氨基化合物(肽)。它能与吗啡受体结合,产生跟吗啡、鸦片剂一样的止痛效果和欣快感。等同天然的镇痛剂。在内啡肽的激发下,人的身心处于轻松愉悦的状态中,免疫系统实力得以强化,并能顺利入梦,消除失眠症。
内啡肽有助于修复我们的身体,当内啡肽分泌的时候,你会觉得心情非常的宁静和喜悦,充满了力量和信心,使人愉乐,使人的分泌出好的激素,改善人的代谢和一些炎症,其中一些激素通过游离脂肪酸粘合进入细胞膜内,有效杀灭癌细胞。
上实施例仅用于阐述本发明,而本发明的保护范围并非仅仅局限于以上实施例。所述技术领域的普通技术人员依据以上本发明公开的内容和各参数所取范围,均可实现本发明的目的。
Claims (7)
1.一种保健胶囊,其特征在于,该胶囊包括胶囊壳体和胶囊内组合物,
所述胶囊壳体包括如下质量百分比组分:明胶:40-60%,可可粉:1-3%,可可脂:1.5-3%,甘油:8-15%,二氧化钛:0.5-1%,余量的水;
所述胶囊内组合物包括如下质量百分比组分:β-烟酰胺单核苷酸:2-5%,胶原蛋白:2-5%,异构化乳糖:3-7%,植物甾醇:0.2-0.5%,余量的水。
2.如权利要求1所述的一种保健胶囊,其特征在于,所述胶囊内组合物还包括黑芝麻油,所述黑芝麻油的质量百分比含量为15-30%。
3.如权利要求1所述的一种保健胶囊,其特征在于,所述胶囊内组合物还包括沉香精油,所述沉香精油的质量百分比含量为0.5-1%。
4.如权利要求1所述的一种保健胶囊,其特征在于,所述胶囊内组合物还包括玉米油,所述玉米油的质量百分比含量为5-15%。
5.如权利要求1所述的一种保健胶囊,其特征在于,所述胶囊内组合物还包括葵花籽油,所述葵花籽油的质量百分比含量5-15%。
6.如权利要求1所述的一种保健胶囊,其特征在于,所述胶囊内组合物还包括维生素,所述维生素的质量百分比含量为1-3%。
7.如权利要求1所述的一种保健胶囊,其特征在于,所述胶囊内组合物还包括益生菌,所述益生菌的质量百分比含量为0.5-1%。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010797892.8A CN111972664A (zh) | 2020-08-10 | 2020-08-10 | 一种保健胶囊 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010797892.8A CN111972664A (zh) | 2020-08-10 | 2020-08-10 | 一种保健胶囊 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111972664A true CN111972664A (zh) | 2020-11-24 |
Family
ID=73445366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010797892.8A Pending CN111972664A (zh) | 2020-08-10 | 2020-08-10 | 一种保健胶囊 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111972664A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113797222A (zh) * | 2021-10-19 | 2021-12-17 | 广州生基科技有限公司 | 氧胶囊、其制备方法与应用 |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002179560A (ja) * | 1999-02-26 | 2002-06-26 | Shionogi & Co Ltd | 服用性を改良した咀嚼型ソフトカプセル剤およびその製法 |
CN1478547A (zh) * | 2002-08-28 | 2004-03-03 | 赵晓红 | 胶原蛋白保健胶囊 |
CN103054124A (zh) * | 2013-01-14 | 2013-04-24 | 中山市国林沉香科学研究所 | 沉香保健饮料及其制备方法 |
CN103689595A (zh) * | 2013-12-12 | 2014-04-02 | 天津科技大学 | 一种乳酸菌软胶囊及其制备方法 |
CN105709045A (zh) * | 2014-12-05 | 2016-06-29 | 重庆安格龙翔医药科技有限公司 | 一种具有减肥作用的中药软胶囊 |
CN108142630A (zh) * | 2017-12-27 | 2018-06-12 | 湖北和格复合骨胶原生物科技有限公司 | 一种具有排毒养颜功效的软糖产品及其制备方法 |
CN108771661A (zh) * | 2018-05-29 | 2018-11-09 | 上海天龙生物科技有限公司 | 一种植物甾醇番茄红素软胶囊 |
US20200009170A1 (en) * | 2016-09-13 | 2020-01-09 | Megumi Tanaka | Sleep display agent property and method for improving sleep disorders |
CN111035012A (zh) * | 2019-12-16 | 2020-04-21 | 青岛赛珥生物医学科技有限公司 | 一种抗氧化营养组合胶囊及其制备方法 |
CN111053143A (zh) * | 2019-11-28 | 2020-04-24 | 北京美宝高科技有限责任公司 | 一种富含营养且绿色健康的夹心凝胶糖果及其制备方法 |
WO2020092616A1 (en) * | 2018-10-31 | 2020-05-07 | Rejuvenation Therapeutics | Compositions useful in the treatment of hyperhomocysteinemia |
-
2020
- 2020-08-10 CN CN202010797892.8A patent/CN111972664A/zh active Pending
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002179560A (ja) * | 1999-02-26 | 2002-06-26 | Shionogi & Co Ltd | 服用性を改良した咀嚼型ソフトカプセル剤およびその製法 |
CN1478547A (zh) * | 2002-08-28 | 2004-03-03 | 赵晓红 | 胶原蛋白保健胶囊 |
CN103054124A (zh) * | 2013-01-14 | 2013-04-24 | 中山市国林沉香科学研究所 | 沉香保健饮料及其制备方法 |
CN103689595A (zh) * | 2013-12-12 | 2014-04-02 | 天津科技大学 | 一种乳酸菌软胶囊及其制备方法 |
CN105709045A (zh) * | 2014-12-05 | 2016-06-29 | 重庆安格龙翔医药科技有限公司 | 一种具有减肥作用的中药软胶囊 |
US20200009170A1 (en) * | 2016-09-13 | 2020-01-09 | Megumi Tanaka | Sleep display agent property and method for improving sleep disorders |
CN108142630A (zh) * | 2017-12-27 | 2018-06-12 | 湖北和格复合骨胶原生物科技有限公司 | 一种具有排毒养颜功效的软糖产品及其制备方法 |
CN108771661A (zh) * | 2018-05-29 | 2018-11-09 | 上海天龙生物科技有限公司 | 一种植物甾醇番茄红素软胶囊 |
WO2020092616A1 (en) * | 2018-10-31 | 2020-05-07 | Rejuvenation Therapeutics | Compositions useful in the treatment of hyperhomocysteinemia |
CN111053143A (zh) * | 2019-11-28 | 2020-04-24 | 北京美宝高科技有限责任公司 | 一种富含营养且绿色健康的夹心凝胶糖果及其制备方法 |
CN111035012A (zh) * | 2019-12-16 | 2020-04-21 | 青岛赛珥生物医学科技有限公司 | 一种抗氧化营养组合胶囊及其制备方法 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113797222A (zh) * | 2021-10-19 | 2021-12-17 | 广州生基科技有限公司 | 氧胶囊、其制备方法与应用 |
CN113797222B (zh) * | 2021-10-19 | 2023-08-22 | 广州市生基科技有限公司 | 氧胶囊、其制备方法与应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101181018B (zh) | 生产保健鸡蛋的蛋鸡饲料 | |
CN107518390B (zh) | 一种诺丽酵素及其制备方法 | |
CN102919383A (zh) | 一种含牡丹籽油的调和油及其制备方法 | |
CN107771946A (zh) | 一种有助于中老年人心脑血管健康的配方奶粉及其生产方法 | |
CN106721480A (zh) | 蛋鸡饲料添加剂及其制备方法 | |
CN102228241A (zh) | 健脑益智增强记忆保健食品及其制备方法 | |
CN1711859A (zh) | 成长素酸奶片 | |
CN104287040A (zh) | 以百香果为原料制备生物型饮料 | |
CN102113448A (zh) | 一种高品质肉灵芝快速培育方法 | |
KR20160076821A (ko) | 유리 필수불포화지방산 함량이 높은 발효 식물성 오일 및 그 제조방법 | |
CN108685006A (zh) | 一种欧米伽3固体饮料 | |
KR101205516B1 (ko) | 아라키돈산의 일내(日內) 리듬 정상화용 용도 | |
CN101147527B (zh) | 一种能使鸭蛋具有软化血管和降压作用的饲料及制备方法 | |
CN104739977A (zh) | 玛咖养生壮元酒(片) | |
CN106360691A (zh) | 一种骨质疏松人群适用的富硒食品及其制备方法 | |
CN111972664A (zh) | 一种保健胶囊 | |
CN104757535A (zh) | 黑枸杞减肥片(茶) | |
CN100473415C (zh) | 一种用于心脑血管疾病的保健品 | |
CN104984330A (zh) | 玛咖强肾前列片 | |
CN108902719A (zh) | 一种保健面条及其制备方法 | |
CN108244654A (zh) | 虫草营养早餐粉 | |
CN102776102B (zh) | 一种含有蜂产品的保健酒 | |
CN115669817B (zh) | 防治家禽脂肪肝综合症的饲料添加剂及其制备方法和应用 | |
CN103859517A (zh) | 一种纯天然营养免疫保健饮料的配制方法 | |
CN102894429A (zh) | 羊肚菌红枣浓浆 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201124 |
|
RJ01 | Rejection of invention patent application after publication |